Valter Gattei Selected Research

Integrin alpha4beta1 (VLA-4)

4/2022	Elastin MIcrofibriL INterfacer1 (EMILIN-1) is an alternative prosurvival VLA-4 ligand in chronic lymphocytic leukemia.
3/2020	VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.
1/2019	Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications.
1/2018	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
5/2015	CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Valter Gattei Research Topics

Disease

58	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2022 - 09/2004
21	Neoplasms (Cancer) 01/2022 - 02/2002
10	Lymphoma (Lymphomas) 12/2018 - 10/2005
7	Disease Progression 01/2021 - 12/2004
5	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 06/2003
5	Residual Neoplasm 12/2020 - 02/2002
5	Leukemia 01/2020 - 11/2002
4	Vasculitis (Vasculitides) 04/2021 - 03/2018
4	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 01/2008
4	Hodgkin Disease (Hodgkin's Disease) 01/2003 - 02/2002
3	B-Cell Lymphoma (Lymphoma, B Cell) 10/2021 - 06/2008
3	Lymphocytosis 01/2021 - 06/2009
3	Trisomy (Trisomies) 01/2020 - 11/2013
3	Multiple Myeloma 01/2016 - 05/2002
2	Virus Diseases (Viral Diseases) 11/2021 - 01/2017
2	Fibrosis (Cirrhosis) 11/2021 - 09/2004
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2021 - 09/2004
2	Glomerulonephritis 12/2020 - 07/2015
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2020 - 01/2019
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2018 - 12/2017
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2017 - 01/2004
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2016 - 08/2015
2	Pathologic Complete Response 10/2014 - 01/2008
2	Testicular Neoplasms (Testicular Cancer) 10/2005 - 02/2005
1	Hepatocellular Carcinoma (Hepatoma) 03/2022
1	Chronic Hepatitis C 11/2021
1	Cryoglobulinemia 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Skin Ulcer 12/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Rare Diseases (Rare Disease) 08/2018
1	Angioedema 08/2018
1	Acquired angioedema 08/2018
1	Ovarian Epithelial Carcinoma 01/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 07/2016
1	Renal Insufficiency (Renal Failure) 07/2016
1	Plasma Cell Leukemia 01/2016

Drug/Important Bio-Agent (IBA)

11	Rituximab (Mabthera)FDA Link 04/2021 - 02/2002
10	ibrutinibIBA 05/2022 - 12/2014
10	Biological ProductsIBA 01/2020 - 05/2002
9	fludarabineIBA 01/2022 - 12/2005
8	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022 - 09/2004
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2002
7	Antiviral Agents (Antivirals)IBA 11/2021 - 12/2014
7	AntigensIBA 01/2016 - 09/2004
6	Surface Antigens (Surface Antigen)IBA 01/2016 - 07/2005
5	IntegrinsIBA 04/2022 - 05/2015
5	Integrin alpha4beta1 (VLA-4)IBA 04/2022 - 05/2015
5	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2008
4	Monoclonal AntibodiesIBA 05/2016 - 10/2005
3	Messenger RNA (mRNA)IBA 01/2020 - 03/2002
3	MicroRNAs (MicroRNA)IBA 12/2018 - 10/2014
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2018 - 12/2014
3	CytokinesIBA 09/2004 - 02/2002
2	LigandsIBA 04/2022 - 07/2007
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 04/2022 - 05/2009
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 10/2015
2	InterferonsIBA 11/2021 - 07/2015
2	NucleotidesIBA 01/2021 - 11/2013
2	nasIBA 01/2021 - 12/2020
2	Biomarkers (Surrogate Marker)IBA 04/2020 - 01/2020
2	ChemokinesIBA 01/2018 - 05/2009
2	DNA (Deoxyribonucleic Acid)IBA 07/2016 - 10/2005
2	nutlin 3IBA 11/2013 - 04/2009
2	ZAP-70 Protein-Tyrosine Kinase (ZAP 70 Protein Tyrosine Kinase)IBA 08/2006 - 12/2005
2	Stem Cell FactorIBA 01/2003 - 09/2002
2	Interleukin-3 (Interleukin 3)IBA 01/2003 - 02/2002
2	Interleukin-9 (Interleukin 9)IBA 09/2002 - 02/2002
1	Fibronectins (Fibronectin)IBA 04/2022
1	ElastinIBA 04/2022
1	Azacitidine (5 Azacytidine)FDA Link 03/2022
1	OligonucleotidesIBA 01/2022
1	serum P-component (CIt)IBA 10/2021
1	idelalisibIBA 04/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	Bendamustine Hydrochloride FDA Link 01/2021
1	2,2- bis(hydroxymethyl)- 1- azabicyclo(2,2,2,)octan- 3- oneIBA 01/2021
1	NucleosidesIBA 01/2021
1	Phenobarbital (Luminal)FDA Link 01/2021
1	ElementsIBA 12/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Peptide Elongation Factors (Elongation Factor)IBA 01/2020
1	Hypoxia-Inducible Factor 1IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	OTX015IBA 12/2018
1	ChromatinIBA 12/2018
1	Complement System Proteins (Complement)IBA 08/2018
1	Untranslated RNA (Noncoding RNA)IBA 06/2017
1	Transcription Factors (Transcription Factor)IBA 06/2017
1	3' Untranslated Regions (3' UTR)IBA 01/2017
1	PlatinumIBA 01/2017
1	Natalizumab (Tysabri)FDA Link 01/2016
1	Sirtuin 1IBA 08/2015

Therapy/Procedure

25	Therapeutics 01/2022 - 12/2004
3	Drug Therapy (Chemotherapy) 01/2021 - 12/2005
3	Time-to-Treatment 01/2012 - 01/2008
1	Radiotherapy 12/2017
1	Transplantation 05/2016